scholarly journals Simultaneous myocardial infarction and ischaemic stroke secondary to paradoxical emboli through a patent foramen ovale

2012 ◽  
Vol 12 (4) ◽  
pp. 391-392 ◽  
Author(s):  
Joanna Grogono ◽  
Samantha J Fitzsimmons ◽  
Benoy N Shah ◽  
Dhrubo J Rakhit ◽  
Huon H Gray
Author(s):  
Guillaume Turc ◽  
David Calvet ◽  
Jean-Louis Mas

Cardiac aetiology accounts for approximately 20% of strokes in young adults. Although atrial fibrillation is a leading cause of stroke in the general population, it is uncommon in young adults. In such patients, more diverse causes of ischaemic stroke are observed, including valvular heart diseases, infective endocarditis, Libman–Sacks endocarditis, dilated cardiomyopathies, congenital heart diseases, myocardial infarction, and intracardiac tumours. Patent foramen ovale is commonly observed in young adults with ischaemic stroke, but this association may be incidental in a sizeable proportion of patients. Young adults who are the most likely to have a stroke-related patent foramen ovale are also those with the lowest recurrence risk.


Author(s):  
Naim Mridha ◽  
Eloise Ward ◽  
Samual Hayman ◽  
Arun Dahiya ◽  
Sandhir Prasad

Author(s):  
Palak Shah ◽  
Amado Jimenez-Ruiz ◽  
Andrew Gibson ◽  
Juan C. Vargas-González ◽  
Maria Bres-Bullrich ◽  
...  

2021 ◽  
Vol 13 (2) ◽  
pp. 227-234
Author(s):  
AQM Reza ◽  
Aparajita Karim ◽  
Mahmood Hasan Khan ◽  
Kazi Atiqur Rahman ◽  
Md Aliuzzaman Joarder ◽  
...  

A patent foramen ovale (PFO) is highly prevalent in patients with strokes of unknown cause or cryptogenic strokes (CSs). It has been remained an unsolved question as to whether a PFO should be closed or not to prevent recurrent strokes in patients diagnosed with cryptogenic stroke (CS). A paradoxical embolism through a PFO is pointed as a leading cause of CS, especially in younger patients with low risk factors for stroke. It also remains an unsolved matter on type of anti-coagulation therapy, which would be better for patients with CS and a PFO. In addition, surgical and transcutaneous closure of a PFO has been proposed for the secondary prevention of stroke in patients with CS with PFO. Several randomized controlled trials have been conducted in recent years to test whether a PFO closure gives a significant benefit in the management of CS. Many investigators believed that a PFO was an incidental finding in patients with CS. However, meta-analyses and more recent specific trials have eliminated several confounding factors and possible biases and have also emphasized the use of a shunt closure over medical therapy in patients with CS. Therefore, these latest studies can possibly change the treatment paradigm in the near future. We are reporting a case of cryptogenic ischaemic stroke in middle cerebral artery territory due to paradoxical embolism through a PFO which was successfully closed with a device solely by a Bangladeshi Consultant & his team first time in Bangladesh. Cardiovasc. j. 2021; 13(2): 227-234


Sign in / Sign up

Export Citation Format

Share Document